The study of LAAO cases provides physicians with evidence they can cite when requesting tools for additional protection.

For primary prevention patients at high risk, such as those with a 10-year risk > 10%, the LDL target is less than 70 mg/dL (class 2a recommendation). For this group, treatment begins with a ...

Geography once drove disparity, but access now hinges on how effectively centers can employ modern donor-utilization tools.

Both CV mortality and major bleeding were rarer when antiplatelets weren’t added, with no tradeoff in ischemic events.

Ami Bhatt speaks to Henri Justino about strategies to support right ventricular growth, PA/IVS, and where current advancements can take us in the future.

The vast majority of patients presenting with type 1 NSTEMI undergo invasive coronary angiography in the US, with most receiving PCI, according to an analysis presented this week at CRT 2026. But as ...

At 3 years, Agent still outshined uncoated balloons. Registry data show rapid uptake of the DCB in the year after its FDA approval.

Barbara Casadei talks with host Yael L. Maxwell about tackling her new role as Editor-in-Chief of JAMA Cardiology as well as changing priorities throughout her career.

Final follow-up from the trial shows durable protection against TLF, especially in chronic total occlusions and diffuse long ...

While the strategies didn’t lower NT-proBNP after PCI in acute MI patients, they may suggest a way forward for intervening early.

The study should be the first of many helping to understand the negative CV effects of the drug in an illicit setting, say authors.

In hypothetical situations, physicians chose intensive treatment more often if BP and mobility metrics were available.